Multiple Myeloma
Show Only Open Trials
1.
A Phase 2 Biomarker Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Smoldering Multiple Myeloma
- Protocol ID: BMS CA204-011
2.
A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Mutliple Myeloma
3.
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Millennium
- Disease Status and/or Stage: Relapsed/Refractory Multiple Myeloma
- Protocol ID: MLN 16010
4.
Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed/Refractory Multiple Myeloma
5.
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Onyx Pharmaceuticals
- Disease Status and/or Stage: Relapsed Multiple Myeloma
- Protocol ID: 2011-003
6.
A Phase II Study of Dexamethasone (Decadron), Clarithromycin (Biaxin), and Pomalidomide (CC-4047) for Subjects with Relapsed or Refractory Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
7.
A Phase II Study of Sequential Carfilzomib, Clarithromycin, Lenalidomide, and Dexamethasone (Car-BiRD) Therapy for Subjects with Newly Diagnosed Multiple Myeloma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Newly Diagnosed Multiple Myeloma; No Previous Treatment
8.
BMS CA204007: A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Multiple Multiple and Normal Renal Function, Severe Renal Impairment, or on Dialysis
- Protocol ID: BMS CA204007
9.
A Prospective Study of Optimally Matched-IPA Targeted Haplo-cord Transplantation
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
10.
BMS CA204004: A Phase 3, Randomized, Open-Label Trial of Lenalidomide/dexamethasone with or without Elotuzumab in Relapsed or Refractory Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
11.
A Phase 1/2 Study of MLN9708 Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Untreated Multiple Myeloma
12.
An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: Millennium Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
13.
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: Genentech
- Disease Status and/or Stage: Previously Treated t(4;14)-positive Multiple Myeloma
14.
An Open-Label Phase I Study of BB-10901 (IMGN901, huN901-DM1) in Combination with Lenalidomide and Dexamethasone in Patients with CD56- positive Relapsed or Relapsed/Refractory Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: ImmunoGen, Inc.
15.
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma
- Study Status: Closed to Enrollment
- Sponsor: Onyx Therapeutics
